Related Experiment Videos
Targeting cytokines to inflammation sites
Gill Adams1, Sandrine Vessillier, Hanna Dreja
1Bone and Joint Research Unit, William Harvey Research Institute, St. Bartholomew's and Royal London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK.
Nature Biotechnology
|October 7, 2003
Summary
Engineered latent cytokines, using latency-associated protein (LAP) and interferon-beta (IFN-beta), show extended half-lives and targeted activation at disease sites. This novel approach demonstrated greater therapeutic effects in preclinical models of arthritis.
Area of Science:
- Biotechnology
- Immunology
- Molecular Biology
Background:
- Cytokines are crucial signaling molecules in immunity and disease.
- Short half-lives and lack of specific targeting limit cytokine therapeutic applications.
- Transforming growth factor-beta 1 (TGF-beta 1) latency-associated protein (LAP) can confer stability and control protein activity.
Purpose of the Study:
- To engineer a latent cytokine with an extended half-life and disease-specific activation.
- To investigate the therapeutic potential of latent versus active interferon-beta (IFN-beta) in inflammatory disease models.
Main Methods:
- Engineered fusion proteins combining LAP, a matrix metalloproteinase (MMP) cleavage site, and IFN-beta.
- Assessed cytokine latency, half-life, and activation by disease-specific fluids (CSF, synovial fluid).
- Evaluated therapeutic efficacy of latent and active constructs in arthritic mouse models via intramuscular DNA injection.
Main Results:
- Engineered LAP-MMP-IFN-beta constructs exhibited a long in vivo half-life (55 h) due to the LAP disulfide-linked shell.
- Latency was dependent on LAP disulfide bonds; mutations abolished latency.
- Latent cytokines were specifically activated by cerebrospinal fluid (CSF) and synovial fluid from inflammatory disease patients, but not by serum.
- Latent cytokine administration showed greater therapeutic effects in arthritic mice compared to active forms.
Conclusions:
- Engineered latent cytokines offer a promising strategy for prolonging half-life and achieving targeted activation.
- This approach holds potential for developing more effective therapies for inflammatory diseases.
- The LAP-MMP-IFN-beta system provides a controllable platform for cytokine-based therapeutics.